A Cohort Study on the Efficacy of Bariatric Surgery for Rapidly Progressing Diabetic Nephropathy

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06661174

Acronym

EBSDKD

Enrollment

100

Registered

2024-10-28

Start date

2023-10-01

Completion date

2025-10-30

Last updated

2024-10-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bariatric Surgeries, Diabetic Nephropathy

Brief summary

Establish a cohort of diabetic kidney disease(DKD) patients with intensive weight loss treatment to evaluate the impact of intensive weight loss treatment on the renal prognosis of DKD and construct a prediction model for the improvement of renal outcomes after weight loss.

Interventions

PROCEDUREBariatric surgery

Laparoscopic sleeve gastrectomy or laparoscopic gastric bypass based on β-cell function

OTHERNon-surgical therapy

Diet management，exercise，metformin，GLP-1 receptor agonists and other drugs which can lose weight.

Study design

Observational model

COHORT

Time perspective

OTHER

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Age 18 to 65 years old; * BMI\>25Kg/m2 or abdominal obesity (i.e. waist circumference\>90cm for men and\>85cm for women); * eGFR\<30ml/min/1.73m2 or urinary microalbumin≥300mg/g, eGFR\<60ml/min/1.73m2.

Exclusion criteria

* Patients who are taking glucocorticoids; * Combined with tumors; ③Combined with autoimmune diseases; ④Serum albumin\<25g/L.

Design outcomes

Primary

Measure	Time frame
Total weight loss	1st, 3rd, 6th and 12th month after intervention, respectively.

Secondary

Measure	Time frame
Glomerular filtration rate	1st, 3rd, 6th and 12th month after intervention, respectively.
Fasting blood glucose	1st, 3rd, 6th and 12th month after intervention, respectively.
Average blood glucose from continuous glucose monitoring	1st, 3rd, 6th and 12th month after intervention, respectively.
Postprandial 2-hour blood glucose	1st, 3rd, 6th and 12th month after intervention, respectively.
Serum creatinine	1st, 3rd, 6th and 12th month after intervention, respectively.
Waist circumference and hip circumference	1st, 3rd, 6th and 12th month after intervention, respectively.
Urinary microalbumin and other Urinalysis indexes	1st, 3rd, 6th and 12th month after intervention, respectively.
Medication status	1st, 3rd, 6th and 12th month after intervention, respectively.
HbA1c	1st, 3rd, 6th and 12th month after intervention, respectively.

Countries

China

Contacts

Primary ContactNianrong Zhang

znrsd@163.com+86 188 1048 8650

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026